Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $21.15 Consensus Price Target from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been assigned a consensus rating of “Hold” from the twenty-three analysts that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $21.1522.

Several analysts have commented on the stock. Wolfe Research cut shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price for the company. in a research note on Wednesday, July 15th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 15th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, June 16th. Citizens Jmp reiterated a “market outperform” rating and issued a $30.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, August 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Friday, July 17th.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $12.68 on Friday. The stock’s 50-day moving average is $13.02 and its two-hundred day moving average is $13.41. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -3.77 and a beta of 1.82. Intellia Therapeutics has a 1 year low of $7.95 and a 1 year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.80). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The firm had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $12.98 million. During the same quarter in the prior year, the business earned ($0.98) EPS. Intellia Therapeutics’s quarterly revenue was down 46.4% compared to the same quarter last year. As a group, research analysts predict that Intellia Therapeutics will post -3.21 EPS for the current year.

Insider Activity

In related news, CAO Michael P. Dube sold 2,641 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the transaction, the chief accounting officer directly owned 66,886 shares in the company, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Comerica Bank raised its holdings in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Intellia Therapeutics during the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Intellia Therapeutics in the third quarter worth $30,000. Freestone Grove Partners LP bought a new position in shares of Intellia Therapeutics during the 2nd quarter worth about $33,000. Finally, Nykredit A S acquired a new position in shares of Intellia Therapeutics during the second quarter valued at about $33,000. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.